What TESARO's Phase 3 NOVA Results Mean For Myriad Genetics
October 10, 2016 at 13:14 PM EDT
Barclays found that TESARO Inc (NASDAQ: TSRO)'s final stage results on NOVA and its indication to pursue a wider label for the drug ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.